How effective are ketamine or esketamine in treatment-resistant depression?
European Psychiatry November 17, 2023 N. Veluri, Z. Mansuri 1 citation
Introduction Globally, depression affects millions of individuals. A third of depression patients meet the criteria for treatment-resistant depression (TRD). The N-methyl-D-aspartate receptor antagonist, ketamine, improved depressive symptoms in a span of 24-hours. Recently, the FDA approved esketamine, an enantiomer of ketamine for TRD. Objectives To determine the effectiveness of ketamine and...